Mission Statement, Vision, & Core Values (2026) of Harbin Gloria Pharmaceuticals Co., Ltd.

Founded on March 27, 2000 and listed on the Shenzhen Stock Exchange as 002437.SZ, Harbin Gloria Pharmaceuticals Co., Ltd. is a Harbin-headquartered drugmaker with a portfolio of over 200 registered medicines spanning cardiovascular, cerebrovascular, musculoskeletal, anti-infective and anti-tumor therapies; as of late 2025 it employs approximately 2,703 people and operates multiple internationally certified production facilities, reporting 2.44 billion RMB in revenue for 2024 (a 7.06% decline year-on-year) alongside a net income of 232.76 million RMB (up 93.43%), while its mission to deliver the highest-quality healthcare products through premium sourcing, cutting-edge technology and rigorous testing, its vision to lead the medical field via customer-centric R&D and ethical practice, and its core values of innovation, integrity, cooperation, tolerance and responsibility collectively drive strategic decisions and market positioning-dive into the full article to examine how these pillars shape the company's trajectory.

Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ) - Intro

• Headquarters: Harbin, Heilongjiang Province, China
• Listing: Shenzhen Stock Exchange - 002437.SZ
• Foundation date: March 27, 2000
• Employees: ~2,703 (late 2025)
• Registered medicines: >200

• Develop safe, effective and accessible medicines that improve patient outcomes across major therapeutic areas, particularly cardiovascular and oncology care.
• Deliver long‑term value to stakeholders through disciplined R&D investment, quality manufacturing and commercial excellence.
• Maintain compliance with international regulatory standards to support global market access.

• Be recognized as a leading Chinese innovator and reliable supplier in targeted therapeutic segments, expanding global reach while preserving product quality and patient safety.
• Transform into an R&D‑driven enterprise with sustainable profitability and a diversified international presence.

• Patient‑centricity: prioritize therapeutic benefit and safety in product design and lifecycle management.
• Quality & Compliance: adhere to GMP and international regulatory requirements across production sites.
• Innovation: invest in R&D to replenish and upgrade the portfolio of >200 registered medicines.
• Integrity & Transparency: governance and reporting aligned with listing requirements on Shenzhen Stock Exchange.
• Operational Efficiency: optimize cost structure while protecting margins and R&D productivity.

• Pipeline strengthening: allocate R&D resources to high‑value cardiovascular, cerebrovascular and oncology candidates.
• Manufacturing & quality: maintain and expand internationally certified facilities to support export and tender opportunities.
• Commercial optimization: focus on core therapeutic areas and lifecycle management of existing brands to stabilize revenue amid market pressures.
• Cost & margin management: improve gross and operating margins following FY2024 results where net income rose sharply despite revenue decline.

• Multiple production facilities with international certifications supporting domestic supply and export compliance.
• R&D centers and regulatory affairs teams for clinical development and approvals across the product portfolio.
• Sales & distribution network targeting hospitals, pharmacies and institutional procurement channels in China and select overseas markets.

Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ) - Overview

Mission Statement

Harbin Gloria Pharmaceuticals' mission is to provide the highest quality medical and healthcare products to our customers. We believe in sourcing the best quality materials, utilizing cutting-edge technology, and providing quality assurance through testing and rigorous internal standards.

• Quality-first focus: end-to-end QA/QC with batch testing and traceability across raw materials and finished products.
• Technology-driven R&D: continuous investment in formulation, process optimization, and analytical methods.
• Supply-chain integrity: supplier qualification, incoming material testing and contingency sourcing.
• Regulatory compliance: adherence to GMP, national pharmacopeia standards, and international export requirements.

The mission underscores the company's dedication to delivering superior pharmaceutical products by emphasizing quality, technological advancement, and stringent quality control measures. Emphasis on sourcing best quality materials and utilizing cutting-edge technology highlights commitment to innovation and excellence in product development.

Operational and strategic metrics (latest reported fiscal year)

Core components of the mission in practice

• Raw material sourcing: multi-tier supplier audits with incoming testing failure rate kept below 0.8%.
• Quality assurance: >99% batch release pass rate after in-house and third-party analytical verification.
• Process control: implementation of PAT (process analytical technology) in 45% of production lines.
• Certification & compliance: GMP recertification cycles completed on schedule for all sites.

How the mission aligns with strategic goals

• Enhancing healthcare outcomes: expanding product portfolio in critical therapeutic categories (cardio-metabolic, anti-infectives, and sterile injectables).
• Meeting medical community needs: targeted clinical collaborations and hospital partnerships to increase formulary access.
• Investor and stakeholder trust: sustained dividend policy and reinvestment in R&D to support long-term pipeline value.

Key performance indicators tied to mission execution

Stakeholder trust and external communication

• Transparent reporting: periodic disclosure of QA incidents, recalls (if any), and corrective actions in annual reports and interim filings.
• Third-party validation: use of accredited labs and certification bodies for critical quality metrics.
• Investor engagement: regular earnings calls, investor days, and the linked deep-dive analysis for shareholders: Breaking Down Harbin Gloria Pharmaceuticals Co., Ltd Financial Health: Key Insights for Investors

Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ) - Mission Statement

• Customer-centricity: deliver safe, effective and accessible pharmaceutical products tailored to patient and healthcare provider needs.
• Innovation-driven R&D: prioritize development of differentiated therapeutics and formulation improvements to expand therapeutic portfolios.
• Ethical business conduct: maintain compliance, transparency and corporate social responsibility across manufacturing, distribution and partnerships.
• Operational excellence: optimize supply chain, quality systems and cost control to ensure reliable product supply and margin protection.
• Stakeholder value: balance patient outcomes, employee development, and shareholder returns.

• Lead the medical and healthcare field through integrated capabilities across research, development, manufacturing and commercial execution.
• Build lasting customer relationships via service, clinical support and post-market surveillance, reinforcing trust with hospitals, distributors and patients.
• Invest in R&D pipelines and platform technologies to generate sustainable new product flow and life-cycle enhancements for existing assets.
• Embed ethical and sustainable practices in governance, environmental stewardship, and community health initiatives.

• R&D funding directed toward high-unmet-need therapeutic areas and improved-release formulations to capture higher-value market segments.
• Capital expenditure prioritized for GMP upgrades, capacity for specialty product lines, and digital quality systems to reduce batch failure and recalls.
• Commercial investment targeted to strengthen hospital penetration, key account management, and real-world evidence generation for core products.

• Compliance frameworks and quality management systems aligned with CNMP/GMP and international supplier audits.
• Transparent reporting and board oversight to ensure ethical marketing, fair pricing practices and environmental controls.
• Community health initiatives and patient education programs focused on drug safety and adherence.

Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ) - Vision Statement

• Innovation: continuous R&D investment to expand pipelines and optimize manufacturing processes.
• Integrity: transparent governance, compliance with regulatory standards, and high-quality control across operational stages.
• Cooperation: strategic alliances with research institutes, suppliers, distributors, and international partners.
• Tolerance: inclusive culture that values diverse expertise and perspectives across teams and regions.
• Responsibility: environmental stewardship, patient-centric access programs, and community health initiatives.

• Innovation - KPI: number of active clinical/preclinical projects (20+), annual patent filings (double-digit filings per year).
• Integrity - KPI: zero severe regulatory non-compliance events; third-party audit pass rate >95%.
• Cooperation - KPI: number of strategic partnerships (10+), share of revenue from partnered products (~15%).
• Tolerance - KPI: employee diversity index improvement year-on-year; internal promotion rate for underrepresented groups >20%.
• Responsibility - KPI: percentage of waste recycled (>70%), philanthropic contributions (RMB millions annually), and community health programs served (thousands of beneficiaries).

• Scale R&D: increase R&D spend to target 7-8% of revenue over next 3 years to accelerate novel formulations and generics lifecycle management.
• Strengthen governance: enhance transparency with expanded ESG reporting and continual compliance upgrades.
• Expand partnerships: deepen collaborations with hospitals and biotech firms to accelerate commercialization and international registration.
• Operational sustainability: implement energy-efficiency projects and wastewater treatment upgrades across plants to meet stricter environmental standards.
• Patient access: expand distribution networks and assistance programs to improve drug accessibility in lower-tier cities and emerging markets.